DPYSL2 and neurofibromatosis type 1: Inhibition of CRMP2 phosphorylation with (S)-lacosamide was beneficial in preclinical models of chronic pain including SNI (Moutal et al., 2016), headache (Moutal et al., 2016;1(1).), neurofibromatosis type 1 related pain (Moutal et al., 2017), and even glioblastoma (Moutal et al., 2017).